Cargando…

Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees

OBJECTIVE: This study aimed to compare the molecular, clinical, and pathological characteristics and pedigrees of familial colorectal cancer type X (FCCTX) with those of Lynch syndrome (LS) to provide a theoretical basis for the management of FCCTX. METHODS: Overall, 46 cases of FCCTX and 47 LS prob...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yun, Li, Cong, Zhang, Yuqin, Guo, Tian’an, Zhu, Congcong, Xu, Ye, Liu, Fangqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493642/
https://www.ncbi.nlm.nih.gov/pubmed/32984025
http://dx.doi.org/10.3389/fonc.2020.01603
_version_ 1783582600618573824
author Xu, Yun
Li, Cong
Zhang, Yuqin
Guo, Tian’an
Zhu, Congcong
Xu, Ye
Liu, Fangqi
author_facet Xu, Yun
Li, Cong
Zhang, Yuqin
Guo, Tian’an
Zhu, Congcong
Xu, Ye
Liu, Fangqi
author_sort Xu, Yun
collection PubMed
description OBJECTIVE: This study aimed to compare the molecular, clinical, and pathological characteristics and pedigrees of familial colorectal cancer type X (FCCTX) with those of Lynch syndrome (LS) to provide a theoretical basis for the management of FCCTX. METHODS: Overall, 46 cases of FCCTX and 47 LS probands and affected families were enrolled between June 2008 and September 2018 for this study. Multigene cancer panel tests that included 139 genes were performed for all patients, and variants in each group were described. The clinical, pathological, and pedigree characteristics were also compared between the two groups. RESULTS: In total, 42 variants were detected in 27 (58.7%) cases in the FCCTX group, with BRCA1, BRCA2, POLE, POLD1, ATR, and ATM being the most frequently mutated genes. The mean onset age of colorectal cancer (CRC) was significantly older in the FCCTX group than in the LS group (53.57 ± 12.88 years vs. 44.36 ± 11.26 years, t = −9.204, p < 0.001). The proportion of patients with rectal cancer was also higher in the FCCTX group than in the LS group [43.5% (20/46) vs. 10.6% (5/47), χ(2) = 12.823, p = 0.005]. Within a median follow-up time of 53.9 ± 37.0 months, the proportion of patients who developed metachronous CRC was significantly higher in the LS group than in the FCCTX group [34.0% (16/47) vs. 13.0% (6/46), χ(2) = 5.676, p = 0.017]. When comparing pedigrees, older age at cancer onset and rectal cancer clustering were observed in the FCCTX families. A higher prevalence in male patients was also observed in the FCCTX families. CONCLUSION: FCCTX is an entity distinct from LS, but its genetic etiology remains unknown. A larger multigene panel would be recommended for determining the underlying pathogenic variants. Considering the pathology and moderate penetrance of the CRC link to FCCTX, less stringent surgical treatments and colonoscopy surveillance would be preferable. Rectum preference is a typical feature of FCCTX. Colonoscopy surveillance in FCCTX families could be less intensive, and more attention should be given to male members.
format Online
Article
Text
id pubmed-7493642
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74936422020-09-24 Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees Xu, Yun Li, Cong Zhang, Yuqin Guo, Tian’an Zhu, Congcong Xu, Ye Liu, Fangqi Front Oncol Oncology OBJECTIVE: This study aimed to compare the molecular, clinical, and pathological characteristics and pedigrees of familial colorectal cancer type X (FCCTX) with those of Lynch syndrome (LS) to provide a theoretical basis for the management of FCCTX. METHODS: Overall, 46 cases of FCCTX and 47 LS probands and affected families were enrolled between June 2008 and September 2018 for this study. Multigene cancer panel tests that included 139 genes were performed for all patients, and variants in each group were described. The clinical, pathological, and pedigree characteristics were also compared between the two groups. RESULTS: In total, 42 variants were detected in 27 (58.7%) cases in the FCCTX group, with BRCA1, BRCA2, POLE, POLD1, ATR, and ATM being the most frequently mutated genes. The mean onset age of colorectal cancer (CRC) was significantly older in the FCCTX group than in the LS group (53.57 ± 12.88 years vs. 44.36 ± 11.26 years, t = −9.204, p < 0.001). The proportion of patients with rectal cancer was also higher in the FCCTX group than in the LS group [43.5% (20/46) vs. 10.6% (5/47), χ(2) = 12.823, p = 0.005]. Within a median follow-up time of 53.9 ± 37.0 months, the proportion of patients who developed metachronous CRC was significantly higher in the LS group than in the FCCTX group [34.0% (16/47) vs. 13.0% (6/46), χ(2) = 5.676, p = 0.017]. When comparing pedigrees, older age at cancer onset and rectal cancer clustering were observed in the FCCTX families. A higher prevalence in male patients was also observed in the FCCTX families. CONCLUSION: FCCTX is an entity distinct from LS, but its genetic etiology remains unknown. A larger multigene panel would be recommended for determining the underlying pathogenic variants. Considering the pathology and moderate penetrance of the CRC link to FCCTX, less stringent surgical treatments and colonoscopy surveillance would be preferable. Rectum preference is a typical feature of FCCTX. Colonoscopy surveillance in FCCTX families could be less intensive, and more attention should be given to male members. Frontiers Media S.A. 2020-09-02 /pmc/articles/PMC7493642/ /pubmed/32984025 http://dx.doi.org/10.3389/fonc.2020.01603 Text en Copyright © 2020 Xu, Li, Zhang, Guo, Zhu, Xu and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, Yun
Li, Cong
Zhang, Yuqin
Guo, Tian’an
Zhu, Congcong
Xu, Ye
Liu, Fangqi
Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees
title Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees
title_full Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees
title_fullStr Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees
title_full_unstemmed Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees
title_short Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees
title_sort comparison between familial colorectal cancer type x and lynch syndrome: molecular, clinical, and pathological characteristics and pedigrees
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493642/
https://www.ncbi.nlm.nih.gov/pubmed/32984025
http://dx.doi.org/10.3389/fonc.2020.01603
work_keys_str_mv AT xuyun comparisonbetweenfamilialcolorectalcancertypexandlynchsyndromemolecularclinicalandpathologicalcharacteristicsandpedigrees
AT licong comparisonbetweenfamilialcolorectalcancertypexandlynchsyndromemolecularclinicalandpathologicalcharacteristicsandpedigrees
AT zhangyuqin comparisonbetweenfamilialcolorectalcancertypexandlynchsyndromemolecularclinicalandpathologicalcharacteristicsandpedigrees
AT guotianan comparisonbetweenfamilialcolorectalcancertypexandlynchsyndromemolecularclinicalandpathologicalcharacteristicsandpedigrees
AT zhucongcong comparisonbetweenfamilialcolorectalcancertypexandlynchsyndromemolecularclinicalandpathologicalcharacteristicsandpedigrees
AT xuye comparisonbetweenfamilialcolorectalcancertypexandlynchsyndromemolecularclinicalandpathologicalcharacteristicsandpedigrees
AT liufangqi comparisonbetweenfamilialcolorectalcancertypexandlynchsyndromemolecularclinicalandpathologicalcharacteristicsandpedigrees